- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00947232
Motivational Interviewing to Increase Physical Activity to Treat Depression in People Aging With MS or SCI (inMotion)
May 2, 2017 updated by: Charles Bombardier, University of Washington
The Effectiveness of Physical Activity for Major Depression in People Aging With Multiple Sclerosis or Spinal Cord Injury
This study compares two approaches to helping people who are aging with MS or SCI and are experiencing depressed mood to become more physically active.
The study is carried out entirely by telephone.
There is no need to travel and participants may reside anywhere within the United States.
We will examine the effects of the intervention on overall physical activity, mood, pain, fatigue and general health.
Participants will complete surveys over the phone throughout the study and wear an activity monitor 3 times.
The study is 6 months in length and participants may receive up to $120 for their time and effort.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
People aging with disabilities such as spinal cord injury (SCI) or multiple sclerosis (MS) report high rates of major depression.
Depression frequently adds to the disabilities and suffering in these populations.
Few definitive studies of depression treatments have been done in people with MS and none in SCI.
There are several reasons to explore novel treatments for major depression in these groups.
First, standard treatments, such as antidepressant medications, may not be as effective in people with neurological disabilities.
Next, people with physical disabilities tend to be inactive.
Lack of physical activity has been positively correlated with higher levels of depression.
Longitudinal data and treatment trials suggest that increased physical activity is related to improved mood.
Controlled trials show that increased exercise and physical activity can be effective treatments for major depression in nondisabled older adults.
Previous research by the investigators' group suggests that people with MS are quite interested in exercise and that exercise is a safe and effective treatment for depression in younger, less disabled people with MS.
Exercise may have widespread benefits for people with MS or SCI.
Finally, exercise or increased physical activity represents a low cost, non-stigmatizing, highly accessible potential treatment for depression in people with physical disabilities.
In this study the investigators will determine whether a relatively brief telephone-based intervention to promote physical activity is an effective treatment for major depression in people aging with MS or SCI.
The investigators define "aging" as chronological age greater than 45 years old.
Study Type
Interventional
Enrollment (Actual)
123
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Washington
-
Seattle, Washington, United States, 98195
- University of Washington
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
45 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- aged at least 45 years old
- self-report diagnosis of MS or SCI
- meeting SCID requirements for Major Depressive Disorder (MDD) or dysthymia
- MS: EDSS between 4.0 and 8.0
- SCI: ASIA A-D injury level at or below C4 and they have upper extremity function sufficient to propel a manual wheelchair
- meeting PHQ-9 measure cut-off for depression by scoring more than 10 on the measure
- currently inactive (exercising less than 150 minutes per week)
- response form received from participants' doctor declaring exercise safe for the subject.
Exclusion Criteria:
- significant cognitive impairment
- pressure ulcers on sitting surfaces (or another condition that precludes sitting
- significant obesity (>160% of ideal body weight)
- significant risk factors for beginning moderate physical activity measured with the PAR-Q
- response form received from participants' doctor declaring exercise unsafe for the subject
- a self-reported history of significant Uthoff's effect for those with MS
- psychiatric contraindications such as bipolar disorder, psychosis, active suicidal ideation with intent or plan, or current alcohol or drug dependence. We will include people who remain depressed but are on stable doses of antidepressant medications.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Motivational interviewing
Motivational interviewing for people aging with multiple sclerosis or spinal cord injury to increase physical activity and decrease depression.
|
Motivational interviewing, a proven counseling method that centers on individual goals and motivations, to increase exercise and decrease depression.
|
|
Active Comparator: Education
Education about physical activity for people aging with multiple sclerosis or spinal cord injury to decrease depression.
|
Educational intervention about the benefits of physical activity to decrease depression for people aging with multiple sclerosis or spinal cord injury.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
HAM-D
Time Frame: Baseline, weeks 4, 6, 8, 12, and 24
|
17-item interview based depression severity measure
|
Baseline, weeks 4, 6, 8, 12, and 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
International Physical Activity Questionnaire
Time Frame: Baseline, weeks 4, 6, 8, 12, and 24
|
self-reported measure of weekly light, moderate and vigorous physical activity
|
Baseline, weeks 4, 6, 8, 12, and 24
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Mark Jensen, PhD, University of Washington
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2009
Primary Completion (Actual)
December 1, 2012
Study Completion (Actual)
March 1, 2013
Study Registration Dates
First Submitted
July 24, 2009
First Submitted That Met QC Criteria
July 27, 2009
First Posted (Estimate)
July 28, 2009
Study Record Updates
Last Update Posted (Actual)
May 5, 2017
Last Update Submitted That Met QC Criteria
May 2, 2017
Last Verified
May 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Central Nervous System Diseases
- Nervous System Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Wounds and Injuries
- Trauma, Nervous System
- Spinal Cord Diseases
- Multiple Sclerosis
- Sclerosis
- Spinal Cord Injuries
Other Study ID Numbers
- 36020-J
- H133B080024
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
Cabaletta BioNot yet recruitingProgressive Multiple Sclerosis | Multiple Sclerosis | Multiple Sclerosis (Relapsing Remitting) | Relapsing Multiple Sclerosis (RMS) | Progressive Multiple Sclerosis (PMS) | Multiple Sclerosis (MS) - Relapsing-remitting | Multiple Sclerosis - Relapsing Remitting
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsActive, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple SclerosisJapan
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on Motivational interviewing
-
University of Maryland, BaltimoreMaryland Department of Health and Mental HygieneCompletedFractures, Bone | Smoking, TobaccoUnited States
-
Johns Hopkins UniversityZanvyl and Isabelle Krieger FundCompleted
-
Massachusetts General HospitalCompletedACS - Acute Coronary SyndromeUnited States
-
Washington University School of MedicineNational Institute of Mental Health (NIMH)Completed
-
Qazvin University Of Medical SciencesCompletedObesity, AdolescentIran, Islamic Republic of
-
Veterans Medical Research FoundationThe Tug McGraw FoundationCompleted
-
University of MichiganNational Heart, Lung, and Blood Institute (NHLBI); University of Iowa; American... and other collaboratorsCompletedChildhood ObesityUnited States
-
University of StellenboschUniversity of British Columbia; McMaster UniversityCompletedText Messaging Plus Motivational Interviewing in Promotion of Breastfeeding Among HIV-infected WomenHIV Infections | Breast FeedingSouth Africa
-
Department of Public Health Medicine, MARA University...Not yet recruiting
-
Istituto Auxologico ItalianoNot yet recruitingSleep Apnea, Obstructive | Motivational InterviewingItaly